Marinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.76), $0.14 worse than the analyst estimate of ($0.62). Revenue for the quarter came in at $7.16 million versus the consensus estimate of $9.07 million.

Corporate Guidance

For the fiscal year 2023, the Company expects ZTALMY U.S. net product revenues of between $15 million and $17 million, BARDA revenues in the range of $8 million to $11 million and total GAAP operating expenses, inclusive of SG&A and R&D, to be in the range of $165 to $175 million, of which the company expects stock-based compensation to be approximately $16 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.